The utility of WT1 testing is limited to a subset of AML MRD cases and more recently the quantitative assessment by DNA sequencing of variants in genes known to be recurrently mutated in myeloid malignancies has been proposed as a more broadly applicable measure of AML MRD (6, 9, 14). Here, WT1 is linked to acute myeloid leukemia.